For research use only. Not for therapeutic Use.
VU534(CAT: I040879) is a potent activator of N-acyl phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD), with an EC50 of 0.30 μM, and functions as a dual inhibitor of fatty acid amide hydrolase (FAAH) and soluble epoxide hydrolase (sEH), with IC50 values of 1.2 μM for both enzymes. By activating NAPE-PLD, VU534 enhances efferocytosis, the process by which apoptotic cells are cleared, in a NAPE-PLD-dependent manner. Given its impact on lipid signaling and inflammation, VU534 holds potential for the study of cardiometabolic diseases, including atherosclerosis and metabolic syndrome, making it a valuable tool in Cardiovascular Disease and Metabolic Disease Research.
| CAS Number | 923509-20-0 |
| Synonyms | N-(5,7-dimethyl-1,3-benzothiazol-2-yl)-1-(4-fluorophenyl)sulfonylpiperidine-4-carboxamide |
| Molecular Formula | C21H22FN3O3S2 |
| Purity | ≥95% |
| IUPAC Name | N-(5,7-dimethyl-1,3-benzothiazol-2-yl)-1-(4-fluorophenyl)sulfonylpiperidine-4-carboxamide |
| InChI | InChI=1S/C21H22FN3O3S2/c1-13-11-14(2)19-18(12-13)23-21(29-19)24-20(26)15-7-9-25(10-8-15)30(27,28)17-5-3-16(22)4-6-17/h3-6,11-12,15H,7-10H2,1-2H3,(H,23,24,26) |
| InChIKey | RLHUIVPGYWWIQZ-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C2C(=C1)N=C(S2)NC(=O)C3CCN(CC3)S(=O)(=O)C4=CC=C(C=C4)F)C |
